Key result
Malignant LVH is linked to AF, stroke, and high risk of heart failure progression or CV death.
Identifying malignant LVH using a structural and biomarker-based framework helps recognize a high-risk Stage B heart failure subgroup that may benefit from intensive blood pressure lowering or novel therapies to prevent progression to symptomatic heart failure or cardiovascular death.
Purpose of Review To review malignant left ventricular hypertrophy (LVH) as a dynamic, higher-risk phenotype within Stage B/pre-heart failure (HF), with a focus on its underlying biology, prognostic significance, and potential modifiability. Recent Findings The malignant LVH phenotype has been newly recognized to be associated with atrial fibrillation, stroke, and cognitive impairment. Recent data also suggest that intensive BP lowering may reduce incident malignant LVH and potentially promote phenotype regression. Other novel approaches that have been shown to reduce adverse remodeling in related populations include direct antifibrotic agents, incretin-analogues, and repurposing known HF therapies. Summary The identification of malignant LVH with a structural and biomarker-based framework may identify a subgroup at particularly high risk for progression to symptomatic HF or CV death.
No takes yet. Share an insight, caveat, or question.
Ravi et al. (2026) conducted a review in Malignant left ventricular hypertrophy (Stage B / pre-heart failure). Malignant left ventricular hypertrophy was evaluated on Progression to symptomatic heart failure or cardiovascular death. Malignant left ventricular hypertrophy is associated with atrial fibrillation, stroke, cognitive impairment, and high risk of progression to symptomatic heart failure or cardiovascular death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: